GLORIA-AF

The Global Registry on Long-Term Oral Anti-Thrombotic Treatment in Patients with Atrial Fibrillation compared the use of non-vitamin K oral anticoagulants with warfarin in patients with nonvalvular AF over time.

Design: Prospective, registry

Patients: 15,092

Centers: 544

Countries: 21

Results: Among the cohort, for stroke prevention, 79.9% received oral anticoagulation (non-vitamin K oral anticoagulants, 47.6%; warfarin, 32.3%), 12.1% received antiplatelet agents and 7.8% received no antithrombotic treatment. In North America, 52.1% of patients received non-vitamin K oral anticoagulants, 26.2% received warfarin, 14% received antiplatelet agents and 7.5% received no antithrombotic treatment. In Europe, the rate of adoption of non-vitamin K oral anticoagulants was similar (52.3%). In Asia, it was less (27.7%).

Original Publications:
Huisman MV, et al. J Am Coll Cardiol. 2017;doi:10.1016/j.jacc.2016.11.061.

Healio/Cardiology News Coverage:
Oral anticoagulants underused for stroke prevention in patients with nonvalvular AF